3,3-Ethylenedioxy-17α,21-dihydroxy-19-norpregna-5(10),9(11)-dien-20-one | 345901-63-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3,3-Ethylenedioxy-17α,21-dihydroxy-19-norpregna-5(10),9(11)-dien-20-one
• 英文别名: 2-hydroxy-1-[(8S,13S,14S,17R)-17-hydroxy-13-methylspiro[1,2,4,6,7,8,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,2'-1,3-dioxolane]-17-yl]ethanone
• CAS: 345901-63-5
• 化学式: C₂₂H₃₀O₅
• 分子量: 374.477
• InChiKey: DQCMQKVISNFMMK-RQIDZSJNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Process for preparing17alpha-acetoxy-11beta-[4-n,n(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene -3,20-dione, intermediates useful in the process , and processes for preparing such intermediates
  申请人：——

  公开号：US20030060646A1

  公开（公告）日：2003-03-27

  A compound having general formula (I) in which R 1 is a member selected from the group consisting of —OCH 3 , —SCH 3 , —N(CH 3 ) 2 , —NHCH 3 , —CHO, —COCH 3 and —CHOHCH 3 ; R 2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R 3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R 4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of —O and —N—OR 5 , wherein R 5 is a member selected from the group consisting of hydrogen and alkyl. In addition to providing the compounds of formula (I), the present invention provides methods wherein the compounds of formula (I) are advantageously used, inter alia. to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception. 1

  通式（I）的化合物，其中R1是从以下组中选择的成员：—O ，—S ，—N（CH3）2，—NH ，—CHO，—CO 和—CHOH ; R2是从以下组中选择的成员：卤素，烷基，酰基，羟基，烷氧基，酰氧基，烷基碳酸酯，环戊酰氧基，S-烷基和S-酰基; R3是从以下组中选择的成员：烷基，羟基，烷氧基和酰氧基; R4是从以下组中选择的成员：氢和烷基; X是从以下组中选择的成员：—O和—N—OR5，其中R5是从以下组中选择的成员：氢和烷基。除了提供通式（I）的化合物外，本发明还提供了使用通式（I）的化合物的优点方法，包括拮抗内源性孕激素；诱导月经；治疗子宫内膜异位症；治疗痛经；治疗内分泌激素依赖性肿瘤；治疗子宫肌瘤；抑制子宫内膜增殖；诱导分娩；以及用于避孕。
• PROCESS FOR PREPARING 17ALPHA-ACETOXY-11BETA- 4-N,N-(DIMETHYLAMINO)PHENYL]-21-METHOXY-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES USEFUL IN THE PROCESS, AND PROCESSES FOR PREPARING SUCH INTERMEDIATES
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP1242444B1

  公开（公告）日：2005-07-20
• US6768014B2
  申请人：——

  公开号：US6768014B2

  公开（公告）日：2004-07-27